GlassScriptPhysician profile
Manmohan Gursahani
NPI 1720042336
$2,432.05
in general payments reported to CMS, 2019-2025
27 companies · $594 in 2025
The $594 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $122 · 2021: $108 · 2022: $317 · 2023: $314 · 2024: $409 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $18.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.37 |
| Education | $18.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $452.67 | 2019-2023 | Xtandi |
| Abbvie INC. | $307.92 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $280.00 | 2023-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $207.54 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $181.60 | 2022-2025 | |
| Tolmar, INC. | $164.16 | 2023-2025 | Eligard |
| Bayer Healthcare Pharmaceuticals INC. | $119.28 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $61.56 | 2024-2025 | Provenge |
| Myovant Sciences INC. | $60.96 | 2021-2022 | |
| Pfizer INC. | $52.83 | 2019-2020 | |
| Teleflex LLC | $50.65 | 2021-2025 | Urolift |
| Coloplast Corp | $48.80 | 2023-2024 | Porges Coloplast |
| Angiodynamics, INC. | $46.51 | 2023-2025 | Nanoknife |
| Merck Sharp & Dohme LLC | $45.22 | 2023-2024 | Keytruda, Lynparza |
| Boston Scientific Corporation | $41.53 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36.29 | 2021-2025 | Erleada |
| Urovant Sciences INC | $35.92 | 2022 | |
| Convatec INC. | $33.53 | 2025 | |
| Immunitybio, INC. | $31.98 | 2025 | |
| Telix Pharmaceuticals | $25.33 | 2022 | |
| Endo USA, INC. | $24.99 | 2024 | Xiaflex |
| Accord Healthcare, INC. | $24.51 | 2024 | |
| Neotract INC. | $23.78 | 2020 | |
| Curium US LLC | $21.61 | 2023 | |
| Endo Pharmaceuticals INC. | $21.11 | 2020 | |
| Mission Pharmacal Company | $16.80 | 2019 | |
| Dentsply Ih Ab | $14.97 | 2025 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmohan Gursahani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.